These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22135208)

  • 1. The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction.
    Quarato G; D'Aprile A; Gavillet B; Vuagniaux G; Moradpour D; Capitanio N; Piccoli C
    Hepatology; 2012 May; 55(5):1333-43. PubMed ID: 22135208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
    Watashi K
    Curr Opin Investig Drugs; 2010 Feb; 11(2):213-24. PubMed ID: 20112171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression.
    Quarato G; Scrima R; Ripoli M; Agriesti F; Moradpour D; Capitanio N; Piccoli C
    Biochem Pharmacol; 2014 Jun; 89(4):545-56. PubMed ID: 24726442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.
    Goto K; Watashi K; Murata T; Hishiki T; Hijikata M; Shimotohno K
    Biochem Biophys Res Commun; 2006 May; 343(3):879-84. PubMed ID: 16564500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.
    Phillips S; Chokshi S; Chatterji U; Riva A; Bobardt M; Williams R; Gallay P; Naoumov NV
    Gastroenterology; 2015 Feb; 148(2):403-14.e7. PubMed ID: 25305505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.
    Ma S; Boerner JE; TiongYip C; Weidmann B; Ryder NS; Cooreman MP; Lin K
    Antimicrob Agents Chemother; 2006 Sep; 50(9):2976-82. PubMed ID: 16940091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of alisporivir and its potential in the treatment of hepatitis C.
    Gallay PA; Lin K
    Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple cyclophilins involved in different cellular pathways mediate HCV replication.
    Gaither LA; Borawski J; Anderson LJ; Balabanis KA; Devay P; Joberty G; Rau C; Schirle M; Bouwmeester T; Mickanin C; Zhao S; Vickers C; Lee L; Deng G; Baryza J; Fujimoto RA; Lin K; Compton T; Wiedmann B
    Virology; 2010 Feb; 397(1):43-55. PubMed ID: 19932913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
    Softic L; Brillet R; Berry F; Ahnou N; Nevers Q; Morin-Dewaele M; Hamadat S; Bruscella P; Fourati S; Pawlotsky JM; Ahmed-Belkacem A
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32376613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
    Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
    Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.
    Watashi K; Hijikata M; Hosaka M; Yamaji M; Shimotohno K
    Hepatology; 2003 Nov; 38(5):1282-8. PubMed ID: 14578868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.
    Flisiak R; Horban A; Gallay P; Bobardt M; Selvarajah S; Wiercinska-Drapalo A; Siwak E; Cielniak I; Higersberger J; Kierkus J; Aeschlimann C; Grosgurin P; Nicolas-Métral V; Dumont JM; Porchet H; Crabbé R; Scalfaro P
    Hepatology; 2008 Mar; 47(3):817-26. PubMed ID: 18302285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins.
    Nakagawa M; Sakamoto N; Tanabe Y; Koyama T; Itsui Y; Takeda Y; Chen CH; Kakinuma S; Oooka S; Maekawa S; Enomoto N; Watanabe M
    Gastroenterology; 2005 Sep; 129(3):1031-41. PubMed ID: 16143140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress.
    Piccoli C; Scrima R; Quarato G; D'Aprile A; Ripoli M; Lecce L; Boffoli D; Moradpour D; Capitanio N
    Hepatology; 2007 Jul; 46(1):58-65. PubMed ID: 17567832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication.
    Ando M; Korenaga M; Hino K; Ikeda M; Kato N; Nishina S; Hidaka I; Sakaida I
    Liver Int; 2008 Sep; 28(8):1158-66. PubMed ID: 18410284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8(+) T cell activation.
    Esser-Nobis K; Schmidt J; Nitschke K; Neumann-Haefelin C; Thimme R; Lohmann V
    J Hepatol; 2016 Jun; 64(6):1305-14. PubMed ID: 26921685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.
    Garcia-Rivera JA; Bobardt M; Chatterji U; Hopkins S; Gregory MA; Wilkinson B; Lin K; Gallay PA
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5113-21. PubMed ID: 22802259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors.
    von Hahn T; Ciesek S; Manns MP
    Discov Med; 2011 Sep; 12(64):237-44. PubMed ID: 21955851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on alisporivir in treatment of viral hepatitis C.
    Flisiak R; Jaroszewicz J; Flisiak I; Łapiński T
    Expert Opin Investig Drugs; 2012 Mar; 21(3):375-82. PubMed ID: 22316207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.